|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:P._V._Sindhu
gptkb:Pfizer
gptkb:Schering_AG
|
|
gptkbp:accreditation
|
gptkb:ANVISA
gptkb:MHRA
gptkb:standard
gptkb:MCC
gptkb:CDSCO
gptkb:FDA
gptkb:WHO
gptkb:EMA
TGA
PMDA
|
|
gptkbp:acquisition
|
gptkb:Glenmark_Pharmaceuticals
gptkb:Liva_Nova
Mylan's generics business in India
Mylan's assets
Wockhardt's business
|
|
gptkbp:awards
|
numerous industry awards
|
|
gptkbp:ceo
|
gptkb:Pankaj_R._Patel
|
|
gptkbp:clinical_trial
|
conducts numerous clinical trials
multiple ongoing
|
|
gptkbp:community_engagement
|
healthcare initiatives in local communities
|
|
gptkbp:employees
|
over 25,000
|
|
gptkbp:expansion_plans
|
entering new markets
expanding manufacturing facilities
increasing R& D investment
|
|
gptkbp:financial_performance
|
consistent revenue growth
|
|
gptkbp:focus
|
healthcare
nutrition
animal health
wellness
consumer health
|
|
gptkbp:founded
|
gptkb:1995
|
|
gptkbp:founder
|
gptkb:Pankaj_R._Patel
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:headcount
|
over 25,000
|
|
gptkbp:headquarters
|
gptkb:Ahmedabad,_India
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zydus Cadila
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:innovation
|
focus on innovative drug delivery systems
|
|
gptkbp:invention
|
holds numerous patents in pharmaceuticals
|
|
gptkbp:leadership
|
Pankaj R. Patel as Chairman
Rajiv Modi as Managing Director
senior management team with diverse expertise
|
|
gptkbp:market
|
global
|
|
gptkbp:market_cap
|
approximately $5 billion
|
|
gptkbp:market_segment
|
gptkb:skincare_product
prescription drugs
nutraceuticals
over-the-counter products
|
|
gptkbp:mission
|
to provide affordable healthcare solutions
|
|
gptkbp:parent_company
|
gptkb:Zydus_Group
gptkb:Zydus_Cadila_Healthcare_Limited
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:temple
gptkb:Johnson_&_Johnson
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Bharat_Biotech
gptkb:Abb_Vie
gptkb:Novartis
various global pharmaceutical companies
|
|
gptkbp:partnerships
|
collaborations with research institutions
|
|
gptkbp:products
|
generic drugs
vaccines
biologics
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:WHO
gptkb:EMA
|
|
gptkbp:research_and_development
|
gptkb:Zydus_Research_Centre
focus on diabetes and oncology
|
|
gptkbp:revenue
|
approximately $2 billion
over $2 billion
|
|
gptkbp:social_responsibility
|
education programs
community health programs
environmental sustainability efforts
healthcare access initiatives
|
|
gptkbp:stock_exchange
|
gptkb:BSE
NSE
|
|
gptkbp:subsidiary
|
gptkb:Zydus_Animal_Health
gptkb:Zydus_Cadila_Healthcare
gptkb:Zydus_Healthcare
gptkb:Zydus_Cadila_Animal_Health
gptkb:Zydus_Wellness
|
|
gptkbp:sustainability_initiatives
|
environmental responsibility programs
|
|
gptkbp:values
|
integrity, innovation, and excellence.
|
|
gptkbp:vision
|
to be a global leader in healthcare
|